{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:14:57Z","timestamp":1768583697993,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01AR073015"],"award-info":[{"award-number":["NIH R01AR073015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DK007418"],"award-info":[{"award-number":["T32DK007418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F32HD91025"],"award-info":[{"award-number":["F32HD91025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08DE028946"],"award-info":[{"award-number":["K08DE028946"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["REAC Summer Explore fellowship"],"award-info":[{"award-number":["REAC Summer Explore fellowship"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder marked by painful, recurrent flare-ups and heterotopic ossification (HO) in soft and connective tissues, which can be idiopathic or provoked by trauma, illness, inflammation, or surgery. There are currently no effective treatments for FOP, or for patients with FOP who must undergo surgery. Palovarotene, an investigational retinoic acid receptor-\u03b3 agonist, offers a potential avenue to prevent HO formation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>The patient is a 32\u2009year-old male, who at age 29 enrolled in a study evaluating palovarotene to prevent HO formation in FOP. One year after starting palovarotene, he fell resulting in a left intertrochanteric fracture. He underwent intramedullary nailing of the femur shaft with screw placement at the distal femur. After surgery, he received palovarotene at 20\u2009mg\/day for 4\u2009weeks, then 10\u2009mg\/day for 8\u2009weeks. Imaging 12\u2009weeks after surgery showed new bridging HO at the site of intramedullary rod insertion and distal screw.<\/jats:p>\n<jats:p>Nine months after the left hip fracture, the patient had a second fall resulting in a subdural hematoma, left parietal bone fracture, and right intertrochanteric fracture. He underwent intramedullary nailing of the right hip, in a modified procedure which did not require distal screw placement. Palovarotene 20\u2009mg\/day was started at fracture occurrence and continued for 4\u2009weeks, then reduced to 10\u2009mg\/day for 8\u2009weeks. HO also formed near the insertion site of the intramedullary rod. No HO developed at the right distal intramedullary rod. After each fracture, the patient had prolonged recurrent flare-ups around the hips.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Surgery is only rarely considered in FOP due to the high risks of procedural complications and potential for inducing HO. This case emphasizes the risks of increased flare activity and HO formation from injury and surgery in patients with FOP. The efficacy of HO prevention by palovarotene could not be assessed; however, our observation that palovarotene can be administered in an individual with FOP following surgery with no negative impact on clinical fracture healing, osteointegration, or skin healing will help facilitate future trials testing the role of palovarotene as a therapy for HO.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12891-020-03240-2","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T16:03:58Z","timestamp":1585929838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-\u03b3 agonist palovarotene: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Sukhmani","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kidane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Motamedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saam","family":"Morshed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"3240_CR1","doi-asserted-by":"crossref","unstructured":"Matsuo K, Dalton CR, Barruet E, Hsiao EC. Inflammation in Fibrodysplasia Ossificans Progressiva and other forms of heterotopic ossification. Curr Osteoporosis Rep. 2019:17(6):387\u201394.","DOI":"10.1007\/s11914-019-00541-x"},{"key":"3240_CR2","doi-asserted-by":"crossref","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, Le Merrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics. 2006;38:525\u201327.","DOI":"10.1038\/ng1783"},{"key":"3240_CR3","doi-asserted-by":"crossref","unstructured":"Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. The obligatory role of Activin a in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone. 2018;109:210\u201317.","DOI":"10.1016\/j.bone.2017.06.011"},{"key":"3240_CR4","doi-asserted-by":"crossref","unstructured":"Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Brown Matthew A, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019;85(6):1199\u2013207.","DOI":"10.1111\/bcp.13777"},{"key":"3240_CR5","first-page":"1","volume":"1","author":"FS Kaplan","year":"2019","unstructured":"Kaplan FS, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Int Clini Council FOP. 2019;1:1\u2013111.","journal-title":"Proc Int Clini Council FOP"},{"issue":"9","key":"3240_CR6","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) mutation. J Bone Miner Res. 2016;31(9):1666\u201375.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"3240_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung W, Macolino C, Chi AH, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists. Nat Med. 2011;17(4):454\u201360.","journal-title":"Nat Med"},{"key":"3240_CR8","first-page":"1","volume":"4","author":"FS Kaplan","year":"2011","unstructured":"Kaplan FS, Shore EM, Al MM. The medical management of fibrodysplasia ossificans progressiva:current treatment considerations. Clin Proc Intl Clin Consort FOP. 2011;4:1\u2013100.","journal-title":"Clin Proc Intl Clin Consort FOP"},{"key":"3240_CR9","unstructured":"Kaplan FS, Shore EM, Glaser DL, Emerson S, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2003;1(2):1\u201372."},{"issue":"3","key":"3240_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid. J Pharmacol Exp Ther. 2002;302(3):1055\u201361.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"3240_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1302\/0301-620X.100B7.BJJ-2017-1467.R1","volume":"100B","author":"M Joice","year":"2018","unstructured":"Joice M, Vasileiadis GI, Amanatullah DF. Non-steroidal anti-inflammatory drugs for heterotopic ossification prophylaxis after total hip arthroplasty: a systematic review and meta-analysis. Bone Joint J. 2018;100B(7):915\u201322.","journal-title":"Bone Joint J"},{"issue":"6","key":"3240_CR12","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s11999-014-4076-x","volume":"473","author":"KT Hug","year":"2015","unstructured":"Hug KT, Alton TB, Gee AO. Brooker classification of heterotopic ossification after Total hip Arthroplasty. Clin Orthop Relat Res. 2015;473(6):2154\u20137.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"3240_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1083\/jcb.200112029","volume":"158","author":"AD Weston","year":"2002","unstructured":"Weston AD, Chandraratna RA, Torchia J, Underhill TM. Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002;158(1):39\u201351.","journal-title":"J Cell Biol"},{"issue":"9","key":"3240_CR14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.ajpath.2015.05.007","volume":"185","author":"A Di Rocco","year":"2015","unstructured":"Di Rocco A, Uchibe K, Larmour C, Berger R, Liu M, Barton ER, et al. Selective retinoic acid receptor \u03b3 agonists promote repair of injured skeletal muscle in mouse. Am J Pathol. 2015;185(9):2495\u2013504.","journal-title":"Am J Pathol"},{"issue":"2","key":"3240_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1183\/09031936.00161911","volume":"40","author":"J Stolk","year":"2012","unstructured":"Stolk J, Stockley RA, Stoel BC, Cooper BG, Piitulainen E, Seersholm N, et al. Randomised controlled trial for emphysema with a selective agonist of the \u03b3-type retinoic acid receptor. Eur Respir J. 2012;40(2):306\u201312.","journal-title":"Eur Respir J"},{"issue":"2","key":"3240_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11914-009-0008-1","volume":"7","author":"LL Demer","year":"2009","unstructured":"Demer LL, Tintut Y. Mechanisms linking osteoporosis with cardiovascular calcification. Curr Osteoporosis Rep. 2009;7(2):42\u20136.","journal-title":"Curr Osteoporosis Rep"},{"issue":"4","key":"3240_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nm0411-430","volume":"17","author":"S Khosla","year":"2011","unstructured":"Khosla S. A shift in calcium. Nat Med. 2011;17(4):430\u20131.","journal-title":"Nat Med"},{"issue":"1","key":"3240_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jbm4.10008","volume":"2","author":"EMW Eekhoff","year":"2018","unstructured":"Eekhoff EMW, Netelenbos JC, de Graaf P, Hoebink M, Bravenboer N, Micha D, et al. Flare-up after maxillofacial surgery in a patient with fibrodysplasia ossificans progressiva: an [18F]-NaF PET\/CT study and a systematic review. JBMR Plus. 2018;2(1):55\u20138.","journal-title":"JBMR Plus"},{"issue":"2","key":"3240_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/00005373-199808000-00009","volume":"45","author":"TM Hupel","year":"1998","unstructured":"Hupel TM, Aksenov SA, Schemitsch EH. Muscle perfusion after intramedullary nailing of the canine tibia. J Trauma Acute Care Surg. 1998 Aug;45(2):256\u201362.","journal-title":"J Trauma Acute Care Surg"},{"issue":"Supplement 1","key":"3240_CR20","first-page":"4","volume":"88","author":"I McCarthy","year":"2006","unstructured":"McCarthy I. The Physiology of Bone Blood Flow: A Review. J Bone Joint Surg. 2006;88(Supplement 1):4\u20139.","journal-title":"J Bone Joint Surg"},{"issue":"2","key":"3240_CR21","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0020-1383(10)70002-4","volume":"41","author":"R Pfeifer","year":"2010","unstructured":"Pfeifer R, Sellei R, Pape H. The biology of intramedullary reaming. Injury. 2010;41(2):S4\u20138.","journal-title":"Injury"},{"key":"3240_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trsl.2017.06.004","volume":"186","author":"D Dey","year":"2017","unstructured":"Dey D, Wheatley BM, Cholok D, Agarwal S, Yu PB, Levi B, et al. The traumatic bone: trauma-induced heterotopic ossification. Transl Res. 2017;186:95\u2013111.","journal-title":"Transl Res"},{"issue":"4","key":"3240_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10172","volume":"3","author":"C Meyers","year":"2019","unstructured":"Meyers C, Lisiecki J, Miller S, Levin A, Fayad L, Ding C, et al. Heterotopic ossification: a comprehensive review. JBMR Plus. 2019;3(4):e10172.","journal-title":"JBMR Plus"},{"key":"3240_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coph.2018.03.007","volume":"40","author":"M Pacifici","year":"2018","unstructured":"Pacifici M. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities. Curr Opin Pharmacol. 2018;40:51\u20138.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"3240_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jor.20985","volume":"28","author":"K Shimono","year":"2010","unstructured":"Shimono K, Morrison TN, Tung W, Chandraratna RA, Williams JA, Iwamoto M, et al. Inhibition of ectopic bone formation by a selective retinoic acid receptor \u03b1-agonist: a new therapy for heterotopic ossification? J Orthop Res. 2010;28(2):271\u20137.","journal-title":"J Orthop Res"},{"key":"3240_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bone.2016.06.014","volume":"90","author":"GJ Pavey","year":"2016","unstructured":"Pavey GJ, Qureshi AT, Tomasino AM, Honnold CL, Bishop DK, Agarwal S, et al. Targeted stimulation of retinoic acid receptor-\u03b3 mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Bone. 2016;90:159\u201367.","journal-title":"Bone"},{"key":"3240_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, et al. Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases. Bone. 2018;109:276\u201380.","journal-title":"Bone"},{"issue":"1","key":"3240_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-019-0386-6","volume":"17","author":"R Haviv","year":"2019","unstructured":"Haviv R, Moshe V, De Benedetti F, Prencipe G, Rabinowicz N, Uziel Y. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? Pediatr Rheumatol Online J. 2019;17(1):84.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"3240_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bcp.13823","volume":"85","author":"KL Wentworth","year":"2019","unstructured":"Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019;85(6):1180\u20137.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03240-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-020-03240-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03240-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:21:22Z","timestamp":1617405682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03240-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3240"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03240-2","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The\u00a0phase 2 palovarotene study was sponsored by Clementia, an Ipsen company, and approved by the Institutional Review Board at the University of California, San Francisco. The participant involved in the study gave informed consent and signed an informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish this information was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ECH serves in a volunteer capacity on the registry advisory board of the International Fibrodysplasia Ossificans Progressiva Association; on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. ECH received prior research support through his institution from Regeneron Pharmaceuticals. ECH and KW receive clinical trials research support through their institution from Clementia, an Ipsen company. These pose no conflicts for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}